Navigation Links
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Date:9/13/2007

in medication.

Cephalon also is proactively working with the FDA to emphasize the appropriate patient selection, dosing and administration in the FENTORA label and Risk Minimization Action Plan (RiskMAP). Healthcare professionals and patients may contact Cephalon Medical Services at 1-800-895-5855 or visit http://www.fentora.com for additional prescribing information. PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE

IMPORTANT WARNINGS IN THIS LABEL.

FENTORA contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. FENTORA can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing FENTORA in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the

highest potential for abuse and risk of fatal overdose due to respiratory depression.

FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. Because life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients, FENTORA is contraindicated in the management of acute or postoperative pain. This product is not indicated for use in opioid nontolerant patients.

Patients and their caregivers must be instructed that FENTORA c
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
2. Why IT change management is more important than ever
3. Contrary to popular belief, holidays are an important time to network
4. Californians: Stem cells important enough to go into debt for
5. The use of e-prescribing and electronic health records is accelerating
6. Imaging and Analysis of DIGE Product Information Sheet, Rev B
7. Study affirms information technology-productivity link
8. TrafficCast integrates new information source
9. Rote education fails the Information Age
10. Weather information companies launch data product
11. TeraMedica launches information manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company focused on the development of autologous cell ... Phase 1/2 clinical trial of RCT-01, being tested ... has been enrolled and their tissue biopsy sent ... is comprised of non-bulbar dermal sheath (NBDS) cells ...
(Date:6/29/2015)... ... ... This cutting edge standard making is a madatory tool for use in ... is the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control personnel ... calibration standards, such as those made from didymium glass were only able to operate ...
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... 2015   Veracyte, Inc . (Nasdaq: VCYT ... molecular cytology, today announced that it has been named ... list for the second year in a row. The ... an annual survey of Bay Area-company employees. ... to which Veracyte values our employees and their individual ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3
... 22 Accelerated Community Oncology,Research Network (ACORN) ... and clinical trial network, announced today,that it ... of Business Development.,Webb brings a successful record ... has an exceptional background of work in ...
... Symbol: MS, - US$10 million received based on ... pivotal multiple sclerosis trial - EDMONTON, Sept. 22 ... in the treatment of multiple sclerosis (MS), today,announced that ... its,partner, Eli Lilly and Company., The milestone payment ...
... the Effects of Oral Calcitonin, a,combination of Salmon ... CEDAR KNOLLS, N.J., Sept. 22 Emisphere,Technologies, ... Novartis Pharma AG,and Nordic Bioscience have completed recruitment ... and efficacy of an oral formulation of,salmon calcitonin ...
Cached Biology Technology:ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 2ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... deadly 1918 Spanish influenza pandemic is why it struck ... such as St. Louis spared the fate of the ... health measures? What made the difference, according to two ... (NIH), was not only how but also how rapidly ...
... cell came from remain distinct even after the cell becomes ... in the February 1 issue of Cancer Research. , ... quest to understand the causes of childhood brain cancers, according ... O. Schnuck Family Professor of Neurology at Washington University School ...
... that the risk of HIV transmission may be highest ... a study published in the April 1 issue of ... infection accounted for nearly half of all transmission occurrences ... Canada. , Bluma Brenner, PhD, and Mark Wainberg, PhD, ...
Cached Biology News:Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2
Competitors to lower non-specific signal...
... anti-rabbit IgG FITC is used as ... staining on tissues or culture cells ... in rabbits. It is highly recommended ... omitting the primary antibody, be included ...
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: